Associations Between Continuing Medical Education Participation and Real-world Readiness for Amyloid-targeting Therapies in Alzheimer’s Disease
Chris Kriz1, Sharon Cohen2, Kristin Tomlinson1, Michael Beyer1
1PVI, PeerView Institute for Medical Education, 2Toronto Memory Program
Objective:
To assess the impact of a multi-activity educational curriculum on clinician knowledge, skills, and real-world practice behaviors related to early diagnosis and the implementation of emerging disease-modifying and amyloid-targeting therapies (ATTs) in Alzheimer’s disease (AD).
Background:
The advent of ATTs has transformed AD management, underscoring the need for timely diagnosis and personalized care. Four on-demand CME activities using adaptive, case-based designs aimed to strengthen evidence-based practice, with real-world data analyses assessing readiness for ATT integration.
Design/Methods:
Clinician learners were matched 1:1 with non-participating controls (n=311 matched pairs) based on pre-education characteristics, including specialty, baseline use of AD treatments, prescribing volume, and AD screening activity. Outlier analysis was performed to ensure validity. ATT initiation was tracked from May 2024 through January 2025 across four CME activities (two adaptive learning, two case-based) representing distinct educational interventions and levels of engagement.
Conclusions:
Participation in CME was associated with real-world indicators of clinical readiness for ATT integration. These findings suggest that longitudinal, curriculum-based education can help prepare clinicians to incorporate novel AD therapeutic strategies into evolving standards of care.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.